Salvage treatment of histoplasmosis with posaconazole

Journal of Infection

Volumn 54, Issue 4, 2007, Pages 319-327

  Restrepo, Angela ^a   Tobón, Angela ^a   Clark, Benjamin ^b   Graham, Donald R ^c   Corcoran, Gavin ^d   Bradsher, Robert W ^e   Goldman, Mitchell ^f   Pankey, George ^g   Moore, Thomas ^h   Negroni, Ricardo ⁱ   Graybill, John R ^j  

^a Unidad de Biología Celular y Molecular   (Colombia)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

^c Springfield Clinic   (United States)

^d Stiefel Laboratories Inc   (United States)

^e UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^f INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g OCHSNER CLINIC FOUNDATION   (United States)

^h Center for Infectious Disease   (United States)

ⁱ HOSPITAL F J MUÑIZ   (Argentina)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

more..

Author keywords

Disseminated; Invasive fungal infection; Posaconazole; Salvage treatment

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; EFAVIRENZ; FLUCONAZOLE; INDINAVIR; ITRACONAZOLE; LAMIVUDINE; POSACONAZOLE; STAVUDINE; VORICONAZOLE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE KIDNEY FAILURE; ADRENAL INSUFFICIENCY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD CULTURE; CEREBROSPINAL FLUID CULTURE; CLINICAL TRIAL; COMORBIDITY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRANIAL NEUROPATHY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FEMALE; HEART DISEASE; HISTOPATHOLOGY; HISTOPLASMA CAPSULATUM; HISTOPLASMOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOGONADISM; HYPOKALEMIA; LUNG DISEASE; MALE; MALNUTRITION; MEDICAL DECISION MAKING; MOTOR NEUROPATHY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; POTASSIUM BLOOD LEVEL; RIGOR; SALVAGE THERAPY; SAMPLE SIZE; SIDE EFFECT; SKIN BIOPSY; THORAX PAIN; TREATMENT DURATION; TREATMENT OUTCOME; UREA NITROGEN BLOOD LEVEL; VOMITING;

ADOLESCENT; ADULT; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; CEREBROSPINAL FLUID; ETHMOID SINUSITIS; FEMALE; HISTOPLASMA; HISTOPLASMOSIS; HUMANS; LUNG DISEASES, FUNGAL; MALE; MAXILLARY SINUSITIS; MENINGITIS, FUNGAL; MIDDLE AGED; SALVAGE THERAPY; TREATMENT OUTCOME; TRIAZOLES;

EID: 33947113790     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2006.05.006     Document Type: Article

References (40)

1. Davies SF. Histoplasmosis: update 1989. Semin Respir Infect 5 (1990) 93-104
2. Cano M.V.C., and Hajjeh R.A. The epidemiology of histoplasmosis: a review. Semin Respir Infect 16 (2001) 109-118
3. Panackal A.A., Hajjeh R.A., Cetron M.S., and Warnock D.W. Fungal infections among returning travelers. Clin Infect Dis 35 (2002) 1088-1095
4. Salomon J., Flament Saillour M., De Truchis P., Bougnoux M.E., Dromer F., Dupont B., et al. An outbreak of acute pulmonary histoplasmosis in members of a trekking trip in Martinique, French West Indies. J Travel Med 10 (2003) 87-93
5. Centers for Disease Control and Prevention. Histoplasmosis: protecting workers at risk (1997), Department of Health and Human Services, National Institute for Occupational Safety and Health. Washington: DC. p. 1-22. DHHS (NIOSH) Publication No. 97-146. Available at: [accessed 04.01.05]
6. Wheat J., Sarosi G., McKinsey D., Hamill R., Bradsher R., Johnson P., et al. Practice guidelines for the management of patients with histoplasmosis. Infectious Diseases Society of America. Clin Infect Dis 30 (2000) 688-695
7. Wolf J., Blumberg H.M., and Leonard M.K. Laryngeal histoplasmosis. Am J Med Sci 327 (2004) 160-162
8. Srikrishna A., Sitalakshmi S., Shantala Devi A.M., Damodar P., and D'Souza G.A. Disseminated histoplasmosis in an AIDS patient diagnosed on bone marrow. Indian J Pathol Microbiol 45 (2002) 333-534
9. Verhaert K., Rodriguez M., Mendoza G., Delgadillo J.L., and Casaer P. Polyarthritis and humeral epiphysial separation in an infant with acute disseminated histoplasmosis. Pediatr Infect Dis J 21 (2002) 352-353
10. Saccente M., McDonnell R.W., Baddour L.M., Mathis M.J., and Bradsher R.W. Cerebral histoplasmosis in the azole era: report of four cases and review. South Med J 96 (2003) 410-416
11. Rosenberg J.D., and Scheinfeld N.S. Cutaneous histoplasmosis in patients with acquired immunodeficiency syndrome. Cutis; Cutaneous Medicine for the Practitioner 72 (2003) 439-445
12. Laochumroonvorapong P., DiCostanzo D.P., Wu H., Srinivasan K., Abusamieh M., and Levy H. Disseminated histoplasmosis presenting as pyoderma gangrenosum-like lesions in a patient with acquired immunodeficiency syndrome. Int J Dermatol 40 (2001) 518-521
13. Hott J.S., Horn E., Sonntag V.K., Coons S.W., and Shetter A. Intramedullary histoplasmosis spinal cord abscess in a nonendemic region: case report and review of the literature. J Spinal Disord Tech 16 (2003) 212-215
14. McGraw E.P., Kane J.M., Kleiman M.B., and Scherer L.R. Cervical abscess and mediastinal adenopathy: an unusual presentation of childhood histoplasmosis. Pediatr Radiol 32 (2002) 862-864
15. Martin R.C., Edwards M.J., and McMasters K.M. Histoplasmosis as an isolated liver lesion: review and surgical therapy. Am Surg 67 (2001) 430-431
16. Wong P., Houston S., Power B., Lalor E., and Bain V.G. A case of Histoplasma capsulatum causing granulomatous liver disease and Addisonian crisis. Can J Gastroenterol 15 (2001) 687-691
17. Mazhari N.J., Sakhuja P., Malhotra V., Gondal R., and Puri J. Histoplasmosis of the liver: a rare case. Trop Gastroenterol 23 (2002) 90-91
18. Jain S., Koirala J., and Castro-Pavia F. Isolated gastrointestinal histoplasmosis: case report and review of the literature. South Med J 97 (2004) 172-174
19. Gomes Ferreira O., Vieira Fernandes A., Sebastiao Borges A., Simao Ferreira M., and Mota Loyola A. Orofacial manifestations of histoplasmosis in an HIV-positive patient: a clinical case report. Med Oral 6 (2001) 101-105
20. Lachmanan S.R., Haniza O., Hisham A.N., Subramaniam J., and Merican I. Histoplasmosis presenting with progressively worsening backache: a case report. Ann Acad Med Singapore 30 (2001) 656-658
21. Ayi B.S., and Smith P.W. Man with weight loss, fever, cough, and an abnormal spleen. Clin Infect Dis 37 (2003) 831-833
22. Isotalo P.A., Chan K.L., Rubens F., Beanlands D.S., Auclair F., and Veinot J.P. Prosthetic valve fungal endocarditis due to histoplasmosis. Can J Cardiol 17 (2001) 297-303
23. Tobon A.M., Franco L., Espinal D., Gomez I., Arango M., Trujillo H., et al. Disseminated histoplasmosis in children: the role of itraconazole therapy. Pediatr Infect Dis J 15 (1996) 1002-1008
24. Zimmermann T., Yeates R.A., Laufen H., Pfaff G., and Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 46 (1994) 147-150
25. Gallis H.A., Drew R.H., and Pickard W.W. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 12 (1990) 308-329
26. Espinel-Ingroff A. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (l-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J Clin Microbiol 36 (1998) 2950-2956
27. Connolly P., Wheat J., Schnizlein-Bick C., Durkin M., Kohler S., Smedema M., et al. Comparison of a new triazole antifungal agent, Schering 56592, with itraconazole and amphotericin B for treatment of histoplasmosis in immunocompetent mice. Antimicrob Agents Chemother 43 (1999) 322-328
28. Connolly P., Wheat L.J., Schnizlein-Bick C., Durkin M., Kohler S., Smedema M., et al. Comparison of a new triazole, posaconazole, with itraconazole and amphotericin B for treatment of histoplasmosis following pulmonary challenge in immunocompromised mice. Antimicrob Agents Chemother 44 (2000) 2604-2608
29. National Institutes of Health (Department of Health and Human Services). Common toxicity criteria 2.0 (1998), National Institutes of Health p. 1-35
30. Wheat L.J., Musial C.E., and Jenny-Avital E. Diagnosis and management of central nervous system histoplasmosis. Clin Infect Dis 40 (2005) 844-852
31. Lutz J.E., Clemons K.V., Aristizabal B.H., and Stevens D.A. Activity of the triazole SCH 56592 against disseminated murine coccidioidomycosis. Antimicrob Agents Chemother 41 (1997) 1558-1561
32. Kirkpatrick W.R., McAtee R.K., Fothergill A.W., Loebenberg D., Rinaldi M.G., and Patterson T.F. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 44 (2000) 780-782
33. Courtney R., Pai S., Laughlin M., Lim J., and Batra V. Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. Antimicrob Agents Chemother 47 (2003) 2788-2795
34. Ngo L.Y., Keung A., Aweeka F.T., Hardin T.C., Salfi M., Gontz H., et al. A pharmacokinetic drug interaction study of posaconazole with zidovudine/lamivudine and protease inhibitors in HIV-infected patients. [abstract 1812]. Am Assoc Pharm Sci J 2 (2000). http://www.aapspharmaceutica.com [accessed 20.04.06]
35. Al-Abdely H, Najvar L, Bocanegra R, Graybill JR. SCH-56592 (SCH) therapy of experimental murine cerebral phaeohyphomycosis due to Cladophialophora bantiana (CB) [abstract J-69]. In: Program and abstracts of the38th Interscience Conference of Antimicrobial Agents in Chemotherapy (ICAAC), San Diego, CA; 1998.
36. Bocanegra RA, Johnson EM, Najvar LK, Graybill JR. Use of novel antifungals in treatment of murine phaeohyphomycosis caused by Wangiella dermatitidis (WD) [abstract F-86]. In: Program and abstracts of the 37th Interscience Conference on Antimicrobial Agents Chemotherapy (ICAAC), Toronto, Ontario, Canada; 1997.
37. Gonzalez G, Tijerina R, Najvar L, Bocanegra R, Rinaldi M, Loebenberg D, et al. Therapeutic efficacy of posaconazole (POSA) in a murine Pseudallescheria boydii infection [abstract J-1615]. In: Program and abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Chicago, IL; 2001.
38. Perfect J.R., Cox G.M., Dodge R.K., and Schell W.A. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans. Antimicrob Agents Chemother 40 (1996) 1910-1913
39. Herrin K.V., Miranda A., and Loebenberg D. Posaconazole therapy for systemic coccidioidomycosis in a chimpanzee (Pan troglodytes): a case report. Mycoses 48 (2005) 447-452
40. Pitisuttithum P., Negroni R., Graybill J.R., Bustamante B., Pappas P., Chapman S., et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 56 (2005) 745-755